🇺🇸 FDA
Patent

US 8987227

Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use

granted A61PA61P31/14

Quick answer

US patent 8987227 (Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of use) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P31/14